Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	6.99	5.57	-	-	0	-
Cost of Revenue	5.15	4.02	-	-	-	-
Gross Profit	1.84	1.55	-	-	0	-
Selling, General & Admin	10.76	8.3	2.38	1.08	0.17	0.07
Research & Development	0.08	0.09	-	0.09	-	-
Operating Expenses	10.94	8.46	2.38	1.17	0.17	0.07
Operating Income	-9.1	-6.92	-2.38	-1.17	-0.16	-0.07
Interest Expense	-0.1	-0.12	-	-	-	-
Interest & Investment Income	0	0	-	0	0	-
Other Non Operating Income (Expenses)	-16.15	-16.15	-	-	-	-
EBT Excluding Unusual Items	-25.34	-23.18	-2.38	-1.17	-0.16	-0.07
Impairment of Goodwill	-10.07	-10.07	-	-	-	-
Other Unusual Items	1.26	1.26	-	-	-	-
Pretax Income	-34.15	-31.99	-2.38	-1.17	-0.16	-0.07
Income Tax Expense	-0.01	-0.01	-	-	-	-
Net Income	-34.14	-31.98	-2.38	-1.17	-0.16	-0.07
Net Income to Common	-34.14	-31.98	-2.38	-1.17	-0.16	-0.07
Shares Outstanding (Basic)	11	8	3	4	1	-
Shares Outstanding (Diluted)	11	8	3	4	1	-
Shares Change (YoY)	171.61%	151.73%	-18.37%	317.64%	-	-
EPS (Basic)	-3.17	-3.84	-0.72	-0.29	-0.17	-
EPS (Diluted)	-3.17	-3.84	-0.72	-0.29	-0.17	-
Free Cash Flow	-3.99	-4	-1.78	-1.19	-0.16	-0.14
Free Cash Flow Per Share	-0.37	-0.48	-0.54	-0.29	-0.17	-
Gross Margin	26.31%	27.78%	-	-	100.00%	-
Operating Margin	-130.21%	-124.31%	-	-	-3244.72%	-
Profit Margin	-488.51%	-574.64%	-	-	-3244.66%	-
Free Cash Flow Margin	-57.16%	-71.81%	-	-	-3263.60%	-
EBITDA	-9.01	-6.85	-2.38	-1.17	-	-
EBITDA Margin	-128.88%	-123.02%	-	-	-	-
D&A For EBITDA	0.09	0.07	0.01	0	-	-
EBIT	-9.1	-6.92	-2.38	-1.17	-0.16	-0.07
EBIT Margin	-130.21%	-124.31%	-	-	-	-

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q